Sertraline and Drug-Induced Erythema Nodosum
Yes, sertraline has been implicated in drug-induced erythema nodosum, though this is a rare adverse cutaneous reaction. The FDA drug label for sertraline does not specifically list erythema nodosum, but does document various severe cutaneous disorders among post-marketing reports 1.
Evidence from Drug Labeling
The FDA label for sertraline explicitly mentions "photosensitivity and other severe cutaneous disorders" in post-marketing surveillance 1. While the label lists specific dermatologic reactions including:
- Erythematous rash (infrequent)
- Maculopapular rash (infrequent)
- Photosensitivity reaction (infrequent)
- Bullous eruption (rare)
Erythema nodosum is not explicitly named in the FDA label 1. However, the label does acknowledge that severe skin reactions "potentially can be fatal" have been reported 1.
Evidence from Medical Literature
A 2007 systematic review in the Journal of the American Academy of Dermatology specifically identifies erythema nodosum as a documented cutaneous reaction to SSRIs, including sertraline 2. This review notes that SSRIs can produce various cutaneous reactions and importantly states that "there appears to be cross-reactions between SSRIs, even though they have different chemical structures" 2.
Clinical Context and Mechanism
Drug-induced erythema nodosum represents a hypersensitivity panniculitis that can occur with numerous medications 3, 4. The 2014 review on drug-induced panniculitides confirms that erythema nodosum is "the most frequently reported drug-induced panniculitis" 4. Common causative drugs include oral contraceptives, NSAIDs, antibiotics, and leukotriene-modifying agents 4.
The diagnosis of drug-induced erythema nodosum requires:
- Temporal relationship between drug initiation and symptom onset
- Clinical improvement after drug discontinuation
- Ideally, histopathological confirmation (septal panniculitis without vasculitis) 4, 5
Clinical Recommendation
If a patient on sertraline develops erythema nodosum, discontinue the medication and consider switching to a different class of antidepressants rather than another SSRI, given the documented cross-reactivity within the SSRI class 2. The causative relationship is established through drug history and clinical improvement after discontinuation 4.
Important Caveats:
- Rule out other common causes of erythema nodosum first (streptococcal infection, tuberculosis, sarcoidosis, inflammatory bowel disease, pregnancy) 3
- Obtain histopathological confirmation when possible, as clinical diagnosis alone is insufficient for definitive drug attribution 4
- The reaction is rare but documented, so maintain clinical suspicion when temporal relationship exists